AbbVie’s Humira Is a Textbook Case for Drugmakers Navigating Patent Cliff

Thanks to the success of outgoing CEO Richard Gonzalez, biopharma executives will be studying for years to come how AbbVie navigated the decline of blockbuster Humira.